• Model-Based Approach to Optimize Atazanavir Dose Recommendation for HIV-infected Pediatrics. . Y. Hong., K. Kowalski, J. Zhang, L. Zhu, M. Horga, R. Bertz, M. Pfister, and A. Roy. Antimicrobial Agents and Chemotherapy (in press).
  • Extending the Latent Variable Model for Extra Correlated Longitudingal Dichotomous Responses. M. Hutmacher and J. French. J. PK & PD 2011;38:833-859.
  • A Quantitative Approach for Making Go/No Go Decisions in Drug Development. C. Chuang-Stein, S. Kirby, J. French, K. Kowalski, S. marshall, M. Smith, P. Bycott, and M. beltangagy. Drug Information Journal (in press).
  • Modeling Dropout From Adverse Event Data: Impact of Dosing Regimens Across Pregabalin Trials in the Treatment of Generalized Anxiety Disorder.. L. Lalovic, M. Hutmacher, B. Frame, and R. Miller. J. Clin. Pharm. 2011;51;706-718.
  • Estimating Transformations for Repeated Measures Modeling of Continuous Bounded Outcome Data.. M. Hutmacher, J. French, S. Krishnaswami, and S. Menon. Stats. in Med. 2011;30:935-949.
  • Modeling and Simulations to Support Dose Selection and Clinical Development of SC-75416, a Selective COX-3 Inhibitor for the Treatment of Acute and Chronic Pain.. K. Kowalski, S. Olson, A. Remmers, and M. Hutmacher. Clinical Pharmacology & Therapeutics 2008; 83;857-866.
  • Decision-Making in Drug Development: Application of a Model Based Framework for Assessing Trial Performance.. M. Smith, J. French, K. Kowalski, M. Hutmacher, and W. Ewy. Book chapter in Clinical Trial Simulations edited by H. Kimko and C. Peck, AAPS and Springer, 2011.